Novavax outlines $230M-$270M 2026 revenue target with new Pfizer partnership and cost reduction strategy
Source: SeekingAlpha
2026-02-26 15:09:53 ET
More on Novavax
- Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
- Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
- Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
- Novavax posts Q4 revenue beat and net income for 2025
Read the full article on Seeking Alpha
For further details see:
Novavax outlines $230M–$270M 2026 revenue target with new Pfizer partnership and cost reduction strategy
Novavax Inc.
NASDAQ: NVAX
NVAX Trading
-0.35% G/L:
$9.6701 Last:
2,073,372 Volume:
$9.56 Open:
NVAX Latest News
February 26, 2026 08:42:07 pm
Power Hour Surge: Quantum Breakouts, Biotech Visibility, and Crypto Strategy Running into the Close
February 26, 2026 08:00:00 am
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
February 19, 2026 08:00:00 am
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
NVAX Stock Data
$1,428,366,166
160,874,005
0.11%
93
N/A
Biotechnology & Life Sciences
Healthcare
US
Gaithersburg
